New Antibody Therapy 77A Enhances Immune Response Against Cancers

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody therapy, designated 77A, which has demonstrated potential in enhancing immune responses against various blood cancers and solid tumors. The findings, presented by Jun Wei, M.D., Ph.D., during the 67th American Society of Hematology (ASH) Annual Meeting on December 6, 2025, indicate that the antibody may help overcome treatment resistance seen in conditions such as myeloma and lymphoma.

Mechanism of Action

The therapeutic agent 77A targets a protein known as HSP70, a heat shock protein that tumors exploit to evade the immune system. Typically, HSP70 is overproduced in various cancers, creating an environment that suppresses immune responses while fostering cancer cell survival. By neutralizing HSP70, 77A activates essential immune cells, including T cells and natural killer (NK) cells, thereby enhancing their ability to identify and eradicate cancer cells.

In laboratory settings, 77A has shown significant antitumor effects, not only by stimulating innate and adaptive immune responses but also by improving the efficacy of existing treatments like chemotherapy, radiation therapy, and immune checkpoint inhibitors. In addition, early tests suggested that 77A could effectively complement adoptive T cell therapy, a cutting-edge approach involving the infusion of lab-grown immune cells to combat cancer.

Next Steps and Future Implications

The promising results from preclinical studies indicate that 77A may serve as a versatile new option for cancer immunotherapy. Preliminary tests with human immune cells suggest enhanced immune responses among healthy donors, paving the way for potential clinical trials. Robert Z. Orlowski, M.D., Ph.D., who leads the research team, expressed optimism about the findings, stating, “These results give us confidence that 77A could become a versatile immunotherapy.”

Plans are underway to develop a humanized version of the antibody for further testing in clinical trials, which will assess its effectiveness across multiple cancer types. The study received support from Blood Cancer United (formerly the Leukemia & Lymphoma Society), highlighting the collaborative efforts in advancing cancer treatment.

As researchers continue to explore the capabilities of 77A, the hope is that this innovative therapy will provide new avenues for patients battling various forms of cancer, thereby reshaping the landscape of cancer treatment.